Workflow
Sera Prognostics(SERA)
icon
Search documents
Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024
Prnewswire· 2024-10-28 12:30
SALT LAKE CITY, Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results a ...
Sera Prognostics(SERA) - 2024 Q2 - Earnings Call Transcript
2024-08-09 21:28
Sera Prognostics, Inc. (NASDAQ:SERA) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William Blair Dan Brennan - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review second quarter fiscal year 2024 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I would ...
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
ZACKS· 2024-08-07 22:50
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.70%. A quarter ago, it was expected that this company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%. Over the last four quarters, the company has ...
Sera Prognostics(SERA) - 2024 Q2 - Quarterly Report
2024-08-07 20:14
| --- | --- | |-------|------------------------------------------------------| | | | | | WASHINGTON, DC 20549 ___________________________ | | | FORM 10-Q | SECURITIES AND EXCHANGE COMMISSION (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40606 ___________________________ SERA PROGNOSTICS, I ...
Sera Prognostics(SERA) - 2024 Q2 - Quarterly Results
2024-08-07 20:11
Exhibit 99.1 SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Salt Lake City – August 7, 2024 – Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: • Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Hi ...
SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS
Prnewswire· 2024-08-07 20:05
SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, ...
Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial
Prnewswire· 2024-07-09 12:30
SALT LAKE CITY, July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peerreviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at Christia ...
SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION
Prnewswire· 2024-07-01 12:30
The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, 2024, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization ranki ...
SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES
prnewswire.com· 2024-05-28 12:30
SALT LAKE CITY, May 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased to be included in the preliminary list of the Russell 3000 Index, as it marks another ...
Sera Prognostics(SERA) - 2024 Q1 - Earnings Call Transcript
2024-05-09 03:10
Sera Prognostics, Inc. (NASDAQ:SERA) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & Chief Executive Officer Austin Aerts - Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Sera Prognostics Conference Call to Review First Quarter Fiscal Year 2024 Results. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towa ...